AD Pipeline Update: Turn Therapeutics Launches Trial Evaluating Its Topical IL-36/IL-31 Inhibitor for Eczema July 15, 2025
Boehringer Ingelheim and LEO Pharma Partner to Commercialize and Further Develop IL-36 Blocker Spesolimab (Spevigo) July 14, 2025
Raising the Bar in Atopic Dermatitis: Unpacking the practice-changing implications of the LEVEL UP study in AD